CytomX Therapeutics, Inc.'s ADC candidate, CX-2051, shows promise in colorectal cancer. Click here to read an analysis of ...

GSK plc (NYSE:GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical ADC for metastatic castration-resistant prostate ...

As Tubulis prepares to unveil the first in-human data on its next-generation antibody drug conjugate (ADC) later this month, the German biotech has secured a massive new financing round to kick its ...

GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates, but the Big Pharma’s oncology R&D chief told Fierce to “stay tuned” for the company’s own data. The ...

SPRINGFIELD, Mo. (KY3) - KY3 programming has returned to YouTube TV, Hulu, Fubo, and Peacock. KY3 worked with NBC throughout the week to fix a technical issue related to the outage. KY3 apologizes for ...

The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...

BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, and ...

Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...

A year and half from its inception, Adcytherix SAS has raised a €105 million (US$122 million) series A, enabling it to take the lead antibody-drug conjugate (ADC) program into clinical development ...